This might explain Japan (from BP report):
MSB was on track for ~US$8m in revenues forFY20, however manufacturing issues at partner JCR has resulted in restrictionof new patient access to the therapy in Japan from 13th Apr’20 which willimpact 4QFY20 and likely 1QFY21. JCR is now investing in doubling its capacityand building inventory.
MSB - Most exciting 6 months, page-169
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.29 |
Change
0.005(0.39%) |
Mkt cap ! $1.467B | |||
| Open | High | Low | Value | Volume |
| $1.29 | $1.31 | $1.27 | $1.653M | 1.285M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 16781 | $1.28 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.29 | 9777 | 1 |
View Market Depth
| Last trade - 16.10pm 05/11/2024 (20 minute delay) ? |
| MSB (ASX) Chart |